Trial Watch Edition 11 captures high signal clinical development activity from June 1 to June 15, 2026.
This edition is defined by several major shifts across oncology, cardiometabolic medicine, immunology, neurology and advanced modalities. GSK is challenging imatinib in first line GIST, Nurix is moving the first BTK degrader into Phase 3, and Affinia is taking AAV gene therapy into hereditary cardiac disease.
At the same time, autoimmune CAR T momentum continues to expand across new indications, while large Phase 3 programs show that major operational capital is still moving into high conviction clinical development bets.